Teachers Retirement System of The State of Kentucky Makes New $2.22 Million Investment in Elanco Animal Health Incorporated $ELAN

Teachers Retirement System of The State of Kentucky bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 110,000 shares of the company’s stock, valued at approximately $2,215,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its holdings in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Bowen Hanes & Co. Inc. acquired a new stake in shares of Elanco Animal Health in the third quarter worth $47,626,000. Jupiter Asset Management Ltd. raised its position in Elanco Animal Health by 98.8% in the third quarter. Jupiter Asset Management Ltd. now owns 3,716,849 shares of the company’s stock valued at $74,857,000 after purchasing an additional 1,846,907 shares during the period. Primecap Management Co. CA boosted its holdings in Elanco Animal Health by 3.1% in the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after acquiring an additional 1,543,279 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Elanco Animal Health by 266.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock valued at $38,635,000 after purchasing an additional 1,394,839 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Down 2.0%

NYSE ELAN opened at $23.95 on Friday. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $27.72. The firm’s fifty day simple moving average is $24.43 and its 200-day simple moving average is $21.95. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $11.91 billion, a PE ratio of -49.89, a price-to-earnings-growth ratio of 3.11 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the business posted $0.14 EPS. Elanco Animal Health’s quarterly revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. Leerink Partners lifted their target price on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Barclays assumed coverage on Elanco Animal Health in a research report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target for the company. Morgan Stanley raised their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Finally, Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $27.67.

Insider Activity

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,500 shares of the stock in a transaction dated Thursday, December 11th. The shares were bought at an average cost of $21.33 per share, with a total value of $95,985.00. Following the completion of the transaction, the insider owned 123,082 shares in the company, valued at $2,625,339.06. This trade represents a 3.79% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 22,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was acquired at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the purchase, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. This trade represents a 15.17% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 43,450 shares of company stock valued at $937,883. 0.89% of the stock is owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.